176 related articles for article (PubMed ID: 33989024)
1. Taking Aim at the Undruggable.
Coleman N; Rodon J
Am Soc Clin Oncol Educ Book; 2021 Mar; 41():1-8. PubMed ID: 33989024
[TBL] [Abstract][Full Text] [Related]
2. Drugging the 'undruggable' cancer targets.
Dang CV; Reddy EP; Shokat KM; Soucek L
Nat Rev Cancer; 2017 Aug; 17(8):502-508. PubMed ID: 28643779
[TBL] [Abstract][Full Text] [Related]
3. Emerging Pharmacotherapeutic Strategies to Overcome Undruggable Proteins in Cancer.
Lu Y; Yang Y; Zhu G; Zeng H; Fan Y; Guo F; Xu D; Wang B; Chen D; Ge G
Int J Biol Sci; 2023; 19(11):3360-3382. PubMed ID: 37496997
[TBL] [Abstract][Full Text] [Related]
4. Strategies for targeting undruggable targets.
Zhang G; Zhang J; Gao Y; Li Y; Li Y
Expert Opin Drug Discov; 2022 Jan; 17(1):55-69. PubMed ID: 34455870
[TBL] [Abstract][Full Text] [Related]
5. RAS-targeted therapies: is the undruggable drugged?
Moore AR; Rosenberg SC; McCormick F; Malek S
Nat Rev Drug Discov; 2020 Aug; 19(8):533-552. PubMed ID: 32528145
[TBL] [Abstract][Full Text] [Related]
6. Drugging "undruggable" genes for cancer treatment: Are we making progress?
Duffy MJ; Crown J
Int J Cancer; 2021 Jan; 148(1):8-17. PubMed ID: 32638380
[TBL] [Abstract][Full Text] [Related]
7. Drugging the undruggable proteins in cancer: A systems biology approach.
Pathmanathan S; Grozavu I; Lyakisheva A; Stagljar I
Curr Opin Chem Biol; 2022 Feb; 66():102079. PubMed ID: 34426091
[TBL] [Abstract][Full Text] [Related]
8. Drugging K-Ras
Ni D; Li X; He X; Zhang H; Zhang J; Lu S
Pharmacol Ther; 2019 Oct; 202():1-17. PubMed ID: 31233765
[TBL] [Abstract][Full Text] [Related]
9. KRAS: From undruggable to a druggable Cancer Target.
Uprety D; Adjei AA
Cancer Treat Rev; 2020 Sep; 89():102070. PubMed ID: 32711246
[TBL] [Abstract][Full Text] [Related]
10. Drugging the 'undruggable'. Therapeutic targeting of protein-DNA interactions with the use of computer-aided drug discovery methods.
Radaeva M; Ton AT; Hsing M; Ban F; Cherkasov A
Drug Discov Today; 2021 Nov; 26(11):2660-2679. PubMed ID: 34332092
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in cancer drug discovery targeting RAS.
Wilson CY; Tolias P
Drug Discov Today; 2016 Dec; 21(12):1915-1919. PubMed ID: 27506872
[TBL] [Abstract][Full Text] [Related]
12. Progress on Covalent Inhibition of KRAS(G12C).
Westover KD; Jänne PA; Gray NS
Cancer Discov; 2016 Mar; 6(3):233-4. PubMed ID: 26951837
[TBL] [Abstract][Full Text] [Related]
13. Drugging the undruggable: a computational chemist's view of KRAS
Bodnarchuk MS; Cassar DJ; Kettle JG; Robb G; Ward RA
RSC Med Chem; 2021 Apr; 12(4):609-614. PubMed ID: 34046632
[TBL] [Abstract][Full Text] [Related]
14. Drugging Undruggable Molecular Cancer Targets.
Lazo JS; Sharlow ER
Annu Rev Pharmacol Toxicol; 2016; 56():23-40. PubMed ID: 26527069
[TBL] [Abstract][Full Text] [Related]
15. Reimagining Druggability Using Chemoproteomic Platforms.
Spradlin JN; Zhang E; Nomura DK
Acc Chem Res; 2021 Apr; 54(7):1801-1813. PubMed ID: 33733731
[TBL] [Abstract][Full Text] [Related]
16. The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members.
Verdine GL; Walensky LD
Clin Cancer Res; 2007 Dec; 13(24):7264-70. PubMed ID: 18094406
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in targeting the "undruggable" proteins: from drug discovery to clinical trials.
Xie X; Yu T; Li X; Zhang N; Foster LJ; Peng C; Huang W; He G
Signal Transduct Target Ther; 2023 Sep; 8(1):335. PubMed ID: 37669923
[TBL] [Abstract][Full Text] [Related]
18. Drugging RAS: Know the enemy.
Papke B; Der CJ
Science; 2017 Mar; 355(6330):1158-1163. PubMed ID: 28302824
[TBL] [Abstract][Full Text] [Related]
19. Targeting the MAPK Pathway in KRAS-Driven Tumors.
Drosten M; Barbacid M
Cancer Cell; 2020 Apr; 37(4):543-550. PubMed ID: 32289276
[TBL] [Abstract][Full Text] [Related]
20. Targeting "undruggable" c-Myc protein by synthetic lethality.
Wang C; Fang H; Zhang J; Gu Y
Front Med; 2021 Aug; 15(4):541-550. PubMed ID: 33660217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
